Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 78, Issue 3, Pages 524-532
Publisher
Wiley
Online
2014-03-07
DOI
10.1111/bcp.12373
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of the Effects of Food on the Single-Dose Pharmacokinetics of Trametinib, a First-in-Class MEK Inhibitor, in Patients with Cancer
- (2013) Donna S. Cox et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation-Positive Solid Tumors
- (2013) Cathrine L. Denton et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers
- (2013) May Y. K. Ho et al. XENOBIOTICA
- Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man
- (2012) Ethan Hoffmann et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming bioanalytical challenges in an Onglyza®intravenous [14C]microdose absolute bioavailability study with accelerator MS
- (2012) Xiaohui (Sophia) Xu et al. Bioanalysis
- Precision and Accuracy in the Quantitative Analysis of Biological Samples by Accelerator Mass Spectrometry: Application in Microdose Absolute Bioavailability Studies
- (2011) Lan Gao et al. ANALYTICAL CHEMISTRY
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)
- (2011) Hiroyuki Abe et al. ACS Medicinal Chemistry Letters
- Pharmacokinetics of fexofenadine: Evaluation of a microdose and assessment of absolute oral bioavailability
- (2010) Graham Lappin et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Microdose Pharmacokinetics of IDX899 and IDX989, Candidate HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors, Following Oral and Intravenous Administration in Healthy Male Subjects
- (2009) Xiao-Jian Zhou et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Comparison of a 250 kV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer - fitness for purpose in bioanalysis
- (2008) G. C. Young et al. RAPID COMMUNICATIONS IN MASS SPECTROMETRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now